PLK1

PLK1

A gene on chromosome 16p12.2 that encodes a member of the CDC5/Polo subfamily of serine/threonine protein kinases, which performs several key functions during the M phase of the cell cycle—e.g., regulating centrosome maturation and spindle assembly, removing cohesins from chromosome arms, inactivating anaphase-promoting complex/cyclosome (APC/C) inhibitors, and regulating mitotic exit and cytokinesis.
 
Molecular pathology
Defects in PLK1 are associated with gastric, thyroid and B-cell malignancies, with increased expression linked to a worse prognosis.
Mentioned in ?
References in periodicals archive ?
along with drug profiles like ANs-40, ANS-401, ANS-403, EBC-46, OXT-328, Recombinant Peptide for Dermatology, Immunology and Oncology, Small Molecules to Activate Protein Kinase C for Dermatology and Cancer, Small Molecules to Inhibit PLK1 for Cutaneous Squamous Cell Carcinoma and Vaccine for HPV Associated Skin Cancer.
Tekmira has access to eight InterfeRx licenses at pre-negotiated financial terms, and has identified the first six targets, including ApoB, PLK1, Ebola, WEE1, CSN5 and ALDH2.
Further, the association of PLK1 in both disease aggression and in vitro growth prompted researchers to examine the effects of a small-molecule inhibitor in CCRCC cell lines.
Polo-like kinase-1 (PLK1) was identified as the principal protein kinase that carried out B23 phosphorylation at this site, and these findings point to PLK1 as a very promising cancer drug target.
SF1126 inhibits all four class I PI3K isoforms along with other cancer targets such as mTOR, DNA-PK, PIM1, and PLK1.
Identify the most promising approaches to kinase modulation in cancer and other diseases by examining drug targets including ABL1, EGFR, ERBB2, FLT3, KIT, PDGFRA, PDGFRB, FLT1, FLT4, KDR, JAK2, MET, AKT1, CDC2, CDK2, AURKA, AURKB, PLK1, FRAP1 and PIK3CA.
Among the kinase inhibitors shown to have potent BRD4 activity are the JAK2-FLT3 inhibitor TG-101348 and the PLK1 inhibitors BI-2536 and volasertib.
Alnylam also has the option to co-develop and co-commercialize Tekmira's PLK1 SNALP program under development for the treatment of certain cancers.
PLK1, the polo-like kinase 1 gene, is one of the seven gene targets for which Tekmira has received an InterfeRx license.
Alnylam has retained the option to co-develop and co-commercialize the new company's PLK1 SNALP program for the treatment of certain cancers, which is one of the seven gene targets for which the new company has received an InterfeRx license.